GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huadong Medicine Co Ltd (SZSE:000963) » Definitions » Forward PE Ratio

Huadong Medicine Co (SZSE:000963) Forward PE Ratio : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Huadong Medicine Co Forward PE Ratio?

Huadong Medicine Co's Forward PE Ratio for today is 0.00.

Huadong Medicine Co's PE Ratio without NRI for today is 18.45.

Huadong Medicine Co's PE Ratio for today is 18.65.


Huadong Medicine Co Forward PE Ratio Historical Data

The historical data trend for Huadong Medicine Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huadong Medicine Co Forward PE Ratio Chart

Huadong Medicine Co Annual Data
Trend
Forward PE Ratio

Huadong Medicine Co Quarterly Data
Forward PE Ratio

Competitive Comparison of Huadong Medicine Co's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Huadong Medicine Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huadong Medicine Co's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huadong Medicine Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Huadong Medicine Co's Forward PE Ratio falls into.



Huadong Medicine Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Huadong Medicine Co  (SZSE:000963) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Huadong Medicine Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Huadong Medicine Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Huadong Medicine Co (SZSE:000963) Business Description

Traded in Other Exchanges
N/A
Address
468 Yan’an Road, Floor 7, 9 and 10, Gate No. 1, Building No. 1, Hangzhou, CHN, 310006
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.
Executives
He Ru Fen Supervisors
Hu Bao Zhen Supervisors
Zhou Shun Hua Executives
Shao Ling Min Supervisors
Wan Ling Ling Executives
Fu Hang Director
Yue Jin Director
Chen Bo Secretary Dong
Qin Yun Supervisors
Li Bang Liang Directors, executives
Zhou Jin Bao Directors, executives

Huadong Medicine Co (SZSE:000963) Headlines

No Headlines